There have been limited studies on the association between prognosis and body weight
change in patients with idiopathic pulmonary fibrosis (IPF). This single-center retrospective …

Patients with idiopathic pulmonary fibrosis (IPF) often experience weight loss during the
follow-up period. However, the prevalence and clinical impact of weight loss in these …

Background: Weight loss is frequently reported in patients with idiopathic pulmonary fibrosis
(IPF) and may be associated with worse outcomes in these patients. Objective: The aim of …

Purpose Although safety and tolerability of approved antifibrotics has been reported
extensively, little is known about their effects on weight. We analyzed predictors of weight …

Background Pirfenidone suppresses the decline of forced vital capacity (FVC) in patients
with idiopathic pulmonary fibrosis (IPF). However, IPF progresses in some patients despite …

Methods This multicenter retrospective cohort study investigated 338 patients treated with
pirfenidone between July 2012 and March 2018. Demographics, pulmonary function …

Rationale Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung
disease that has no cure. Many current research efforts center on diagnostic and therapeutic …

Aim The efficacy and safety of pirfenidone have been previously demonstrated in patients
with mild-to-moderate idiopathic pulmonary fibrosis (IPF). However, the effect of pirfenidone …

Introduction Although pirfenidone slows disease progression in patients with idiopathic
pulmonary fibrosis (IPF), in clinical practice, patients often cannot tolerate the recommended …

Objective The association between nutritional status and prognosis of idiopathic pulmonary
fibrosis (IPF) remains unclear. This systematic review and meta-analysis aimed to explore …